New treatments and diagnostic tools for Alzheimer’s disease are showing significant potential, but researchers caution that without parallel reforms in healthcare systems and policy, the benefits may not reach patients effectively.
A Lancet series highlights that drugs such as lecanemab and donanemab, recently approved by the US Food and Drug Administration, represent the most advanced therapies for slowing Alzheimer’s progression to date. These medications target specific proteins in the brain associated with the disease, with efficacy levels comparable to therapies for cancer and autoimmune conditions like rheumatoid arthritis and multiple sclerosis. Alongside these developments, the emergence of blood-based biomarkers offers a path toward earlier and more accessible diagnosis, which researchers describe as a “diagnostic revolution.”
However, the report underscores systemic challenges that could limit the real-world impact of these innovations. The high cost of Alzheimer’s therapies, reliance on complex diagnostic procedures, and uneven quality of symptomatic care risk creating inequities in access. While the scientific community is advancing rapidly, healthcare infrastructure in many regions is not yet prepared to manage the expected rise in cases as populations age. Alzheimer’s disease already represents the most common form of dementia, steadily eroding memory and cognitive function, and affecting patients’ ability to perform daily activities.
Researchers argue that coordinated reforms in healthcare delivery, financing, and public health are essential to meet this challenge. Suggested measures include healthier urban planning, restrictions on alcohol and sugary drinks, and broader community-level interventions to reduce long-term risk factors. At the same time, governments and payers will need to evaluate how to finance high-cost biologic drugs and integrate new testing methods into standard practice.
Importantly, the majority of Alzheimer’s cases occur in individuals with low or moderate risk profiles, meaning that prevention strategies must extend beyond high-risk groups. While blood biomarker tests could make early detection routine in high-income countries, access gaps in low- and middle-income economies remain a concern.
Although lecanemab and donanemab represent progress, clinical studies have noted side effects such as brain bleeds and only modest symptomatic improvements over placebo. This reinforces the need for balanced adoption, where innovation is paired with patient safety, equitable access, and systemic preparedness.
The authors conclude that Alzheimer’s care is entering a new era – but healthcare systems worldwide must adapt quickly to ensure that scientific progress translates into meaningful outcomes for patients and society.
